Corvus Pharmaceuticals Inc美股招股说明书(2026-01-20版)

$150,000,000Shares of Common Stock We are offering $150,000,000 of shares of our common stock, and, in lieu of common stock to certain investors that so choose,pre-funded warrants to purchase shares of our common stock (the “pre-funded warrants”). The purchase price of each pre-funded warrant equals the price per share at which the shares of our common stock are being sold in this offering, minus $0.0001,which is the exercise price of each pre-funded warrant per share. Each pre-funded warrant will be exercisable at any time after thedate of issuance of such pre-funded warrant, subject to an ownership limitation. This prospectus supplement also relates to the Our common stock is listed on the Nasdaq Global Market under the symbol “CRVS.” The last reported sale price of ourcommon stock on the Nasdaq Global Market on January 16, 2026 was $8.05 per share. There is no established public trading marketfor the pre-funded warrants, and we do not expect a market to develop. We do not intend to list the pre-funded warrants on theNasdaq Global Market or any other national securities exchange or nationally recognized trading system. We are a “smaller reporting company” as defined under the federal securities laws and, as such, we have elected to comply withcertain reduced reporting requirements for this prospectus supplement and may elect to do so in future filings. See “ProspectusSupplement Summary — Implications of Being a Smaller Reporting Company.” Investing in our securities involves significant risks. See “Risk Factors” on pageS-13of this prospectus supplement, on page5of theaccompanying base prospectus, and in the documents incorporated by reference into this prospectus supplement for a discussion of thefactors you should consider before investing in our securities. (1)See “Underwriting” beginning on pageS-30for additional information regarding underwriting compensation. We have granted the underwriters an option to purchase up to $22,500,000 of additional shares of our common stock at thepublic offering price, less underwriting discounts and commissions, for 30days after the date of this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the prospectus to which it relates. Any representationto the contrary is a criminal offense. The underwriters expect to deliver the shares or pre-funded warrants, as applicable, on or about Jefferies TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT We provide information to you about this offering of securities in two separate documents that arebound together: (1)this prospectus supplement, which describes the specific details regarding this offeringand also adds to and updates information contained in the accompanying base prospectus and the documentsincorporated by reference in this prospectus supplement and the accompanying base prospectus; and (2)theaccompanying base prospectus, which provides general information, some of which may not apply to thisoffering. Generally, when we refer to this “prospectus,” we are referring to both documents combined. Ifinformation in this prospectus supplement is inconsistent with the accompanying base prospectus or in anydocument incorporated by reference that was filed with the Securities and Exchange Commission (“SEC”)before the date of this prospectus supplement, you should rely on this prospectus supplement. However, if Neither we nor the underwriters have authorized anyone to provide you with any information or tomake any representations other than those contained or incorporated by reference in this prospectussupplement and the accompanying base prospectus or in any free writing prospectus prepared by or onbehalf of us or to which we have referred you. Neither we nor the underwriters take responsibility for, orprovide assurance as to the reliability of, any other information that others may give you. You shouldassume that the information appearing in this prospectus supplement, the accompanying base prospectus,the documents incorporated by reference into this prospectus supplement and the accompanying baseprospectus, and in any free writing prospectus that we may authorize for use in connection with thisoffering, is accurate only as of the date of those respective documents, regardless of the time of delivery of Neither we nor the underwriters are making an offer to sell or soliciting an offer to buy our securities inany jurisdiction where an offer or solicitation is not authorized or in which the person making that offer orsolicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. Weare offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and sales arepermitted. The distribution of this prospectus supplement and the accompanying base prospectus and theoffering